Prevalence of anthracycline‐related cardiac dysfunction in long‐term survivors of adult‐onset lymphoma
Open Access
Abstract
BACKGROUND: Anthracycline‐related heart failure is a leading cause of morbidity in survivors of adult‐onset lymphoma. There is a paucity of information on screening for late‐occurring preclinical disease, which, in turn, has limited guidelines for early detection and intervention. The objectives of this study were to examine the prevalence and risk of cardiac dysfunction, as measured by echocardiography (abnormal left ventricular systolic/diastolic function or strain), in lymphoma survivors who received treatment with anthracyclines and to evaluate the diagnostic yield of blood biomarkers in the asymptomatic setting.METHODS: Lymphoma survivors who underwent hematopoietic cell transplantation (HCT) (n = 78) or received conventional therapy (non‐HCT; n = 77) were compared with each other and with a group of matched controls (n = 51); the study was limited to lymphoma survivors who were >5 years from diagnosis.RESULTS: At a median follow‐up of 9.4 years after diagnosis, 1 in 5 (20.6 %) lymphoma survivors had cardiac dysfunction; the odds of having cardiac dysfunction were 6.6‐fold greater (odds ratio [OR], 6.6; P = .01) among lymphoma survivors compared with matched controls. There was a dose‐dependent risk of cardiac dysfunction according to the cumulative anthracycline dose (controls [referent group], 1‐249 mg/m2 [OR, 4.7; P = .05], and ≥250 mg/m2 [OR, 7.6; P < .01]), but there was no difference in the prevalence of cardiac dysfunction between conventionally treated and HCT survivors. The diagnostic accuracy of cardiac blood biomarkers in the asymptomatic setting was quite poor.CONCLUSIONS: In these long‐term survivors, there was a high rate of cardiac dysfunction that was independent of HCT status. The growing number of lymphoma survivors makes it imperative to identify reliable and cost‐effective strategies to decrease the burden of heart failure in this population. Cancer 2018;124:850‐7. © 2017 American Cancer Society.Keywords
Funding Information
- National Institutes of Health (R21 CA178344‐01)
- National Cancer Institute (R21CA178344)
This publication has 38 references indexed in Scilit:
- Normal Ranges of Left Ventricular Strain: A Meta-AnalysisJournal of the American Society of Echocardiography, 2013
- Incidence and predictors of congestive heart failure after autologous hematopoietic cell transplantationBlood, 2011
- Review of the cardiac long‐term effects of therapy for Hodgkin lymphomaBritish Journal of Haematology, 2011
- 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in AdultsJACC, 2009
- Abnormal NT‐pro‐BNP levels in asymptomatic long‐term survivors of childhood cancer treated with anthracyclinesPediatric Blood & Cancer, 2009
- Anthracycline Cardiotoxicity: From Bench to BedsideJournal of Clinical Oncology, 2008
- Left Ventricular Ejection Fraction and Cardiotoxicity: Is Our Ear Really to the Ground?Journal of Clinical Oncology, 2008
- Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphomaBlood, 2006
- Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of CardiologyJournal of the American Society of Echocardiography, 2005
- Differences in Tachyarrhythmia Detection and Implantable Cardioverter Defibrillator Therapy by Primary or Secondary Prevention Indication in Cardiac Resynchronization Therapy PatientsJournal of Cardiovascular Electrophysiology, 2004